Abstract:
An accumulating body of evidence shows significant similarities between cellular processes involved in neurodegeneration and those involved in neurodevelopment. Most striking, in Alzheimer's disease, cell cycle re‐entry appears to be a pathological signature of the disease that also occur in brain development. Such inappropriate reactivation of a fetal program is likely to play a key role in both the etiology and pathogenesis of disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD:
-
Alzheimer's disease
- ApoE:
-
apolipoprotein E
- AβPP:
-
amyloid‐β protein precursor
- Aβ:
-
amyloid‐β
- Cdk:
-
cyclin‐dependent kinase
- HPG axis:
-
hypothalamic‐pituitary‐gonadal axis
- HRT:
-
hormone replacement therapy
- LH:
-
luteinizing hormone
- PS:
-
presenilin
- ROS:
-
reactive oxygen species
References
Al-Hader AA, Lei ZM, Rao CV. 1997a. Novel expression of functional luteinizing hormone/chorionic gonadotropin receptors in cultured glial cells from neonatal rat brains. Biol Reprod 56: 501–507.
Al-Hader AA, Lei ZM, Rao CV. 1997b. Neurons from fetal rat brains contain functional luteinizing hormone/chorionic gonadotropin receptors. Biol Reprod 56: 1071–1076.
Allen SJ, MacGowan SH, Treanor JJ, Feeney R, Wilcock GK, et al. 1991. Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett 131: 135–139.
Birecree E, Whetsell WO Jr, Stoscheck C, King LE Jr, Nanney LB. 1988. Immunoreactive epidermal growth factor receptors in neuritic plaques from patients with Alzheimer's disease. J Neuropathol Exp Neurol 47: 549–560.
Bothwell M, Giniger E. 2000. Alzheimer's disease: Neurodevelopment converges with neurodegeneration. Cell 102: 271–273.
Bowen RL. 2001. Sex hormones, amyloid protein, and Alzheimer disease. JAMA 286: 790–791.
Bowen RL, Isley JP, Atkinson RL. 2000. An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol 12: 351–354.
Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, et al. 2002. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res 70: 514–518.
Breitner JC, Silverman JM, Mohs RC, Davis KL. 1988. Familial aggregation in Alzheimer's disease: Comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations. Neurology 38: 207–212.
Bruni P, Minopoli G, Brancaccio T, Napolitano M, Faraonio R, et al. 2002. Fe65, a ligand of the Alzheimer's beta-amyloid precursor protein, blocks cell cycle progression by down-regulating thymidylate synthase expression. J Biol Chem 277: 35481–35488.
Busser J, Geldmacher DS, Herrup K. 1998. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 18: 2801–2807.
Chen Y, McPhie DL, Hirschberg J, Neve RL. 2000. The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J Biol Chem 275: 8929–8935.
Chenn A, Walsh CA. 2002. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297: 365–369.
Connor B, Young D, Lawlor P, Gai W, Waldvogel H, et al. 1996. Trk receptor alterations in Alzheimer's disease. Mol Brain Res 42: 1–17.
Connor B, Beilharz EJ, Williams C, Synek B, Gluckman PD, et al. 1997. Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. Mol Brain Res 49: 283–290.
Copani A, Condorelli F, Caruso A, Vancheri C, Sala A, et al. 1999. Mitotic signaling by beta-amyloid causes neuronal death. FASEB J 13: 2225–2234.
Coulson EJ, Paliga K, Beyreuther K, Masters CL. 2000. What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem Int 36: 175–184.
Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, et al. 1987. Oxygen radicals and human disease. Ann Intern Med 107: 526–545.
Crutcher KA, Scott SA, Liang S, Everson WV, Weingartner J. 1993. Detection of NGF-like activity in human brain tissue: Increased levels in Alzheimer's disease. J Neurosci 13: 2540–2550.
Fenton H, Finch PW, Rubin JS, Rosenberg JM, Taylor WG, et al. 1998. Hepatocyte growth factor (HGF/SF) in Alzheimer's disease. Brain Res 779: 262–270.
Ferguson KL, Callaghan SM, O'Hare MJ, Park DS, Slack RS. 2000. The Rb-CDK4/6 signaling pathway is critical in neural precursor cell cycle regulation. J Biol Chem 275: 33593–33600.
Fossgreen A, Bruckner B, Czech C, Masters CL, Beyreuther K, et al. 1998. Transgenic Drosophila expressing human amyloid precursor protein show gamma-secretase activity and a blistered-wing phenotype. Proc Natl Acad Sci USA 95: 13703–13708.
Gomez-Pinilla F, Cummings BJ, Cotman CW. 1990. Induction of basic fibroblast growth factor in Alzheimer's disease pathology. Neuroreport 1: 211–214.
Hardy J. 1997. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20: 154–159.
Harris D, Bonfil D, Chuderland D, Kraus S, Seger R, et al. 2002. Activation of MAPK cascades by GnRH: ERK and Jun N-terminal kinase are involved in basal and GnRH-stimulated activity of the glycoprotein hormone LHbeta-subunit promoter. Endocrinology 143: 1018–1025.
Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, et al. 2000. Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 20: 7951–7963.
Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. 1994. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 51: 896–900.
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, et al. 2001. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017–3023.
Hoffmann J, Twiesselmann C, Kummer MP, Romagnoli P, Herzog V. 2000. A possible role for the Alzheimer amyloid precursor protein in the regulation of epidermal basal cell proliferation. Eur J Cell Biol 79: 905–914.
Janicki SM, Monteiro MJ. 1999. Presenilin overexpression arrests cells in the G1 phase of the cell cycle. Arrest potentiated by the Alzheimer's disease PS2(N141I)mutant. Am J Pathol 155: 135–144.
Janicki SM, Stabler SM, Monteiro MJ. 2000. Familial Alzheimer's disease presenilin-1 mutants potentiate cell cycle arrest. Neurobiol Aging 21: 829–836.
Jorm AF, Jolley D. 1998. The incidence of dementia: A meta-analysis. Neurology 51: 728–733.
Jorm AF, Korten AE, Henderson AS. 1987. The prevalence of dementia: A quantitative integration of the literature. Acta Psychiatr Scand 76: 465–479.
Kang DE, Soriano S, Xia X, Eberhart CG, De Strooper B, et al. 2002. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: Implications for beta-catenin activation in tumorigenesis. Cell 110: 751–762.
Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, et al. 1997. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore longitudinal study of aging. Neurology 48: 1517–1521.
Koo EH. 2002. The beta-amyloid precursor protein (APP) and Alzheimer's disease: Does the tail wag the dog? Traffic 3: 763–770.
Lei ZM, Rao CV, Kornyei JL, Licht P, Hiatt ES. 1993. Novel expression of human chorionic gonadotropin/luteinizing hormone receptor gene in brain. Endocrinology 132: 2262–2270.
Li J, Xu M, Zhou H, Ma J, Potter H. 1997. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell 90: 917–927.
Lukacs H, Hiatt ES, Lei ZM, Rao CV. 1995. Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cycling female rats. Horm Behav 29: 42–58.
Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, et al. 2000. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 54: 833–837.
Masliah E, Mallory M, Alford M, Deteresa R, Saitoh T. 1995. PDGF is associated with neuronal and glial alterations of Alzheimer's disease. Neurobiol Aging 16: 549–556.
McGonigal G, Thomas B, McQuade C, Starr JM, MacLennan WJ, et al. 1993. Epidemiology of Alzheimer's presenile dementia in Scotland, 1974–88. BMJ 306: 680–683.
McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. 1997. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 150: 1933–1939.
Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, et al. 1992. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9: 129–137.
Mulnard RA. 2000. Estrogen as a treatment for Alzheimer disease. JAMA 284: 307–308.
Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, et al. 2000. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's disease cooperative study. JAMA 283: 1007–1015.
Nagy Z, Esiri MM, Smith AD. 1997a. Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathol (Berl) 93: 294–300.
Nagy Z, Esiri MM, Cato AM, Smith AD. 1997b. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol (Berl) 94: 6–15.
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, et al. 2001. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759–767.
Ogawa O, Lee HG, Zhu X, Raina A, Harris PL, et al. 2003. Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell 2: 105–110.
Perry G, Castellani RJ, Hirai K, Smith MA. 1998. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis 1: 45-55.
Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, et al. 2000. Cyclin' toward dementia: Cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J Neurosci Res 61: 128–133.
Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, et al. 2003. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative memory study: A randomized controlled trial. JAMA 289: 2663–2672.
Resnick SM, Henderson VW. 2002. Hormone therapy and risk of Alzheimer disease: A critical time. JAMA 288: 2170–2172.
Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, et al. 1991. Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol 30: 381–390.
Schmitz A, Tikkanen R, Kirfel G, Herzog V. 2002. The biological role of the Alzheimer amyloid precursor protein in epithelial cells. Histochem Cell Biol 117: 171–180.
Schubert D, Cole G, Saitoh T, Oltersdorf T. 1989. Amyloid beta protein precursor is a mitogen. Biochem Biophys Res Commun 162: 83–88.
Schupf N, Kapell D, Nightingale B, Rodriguez A, Tycko B, et al. 1998. Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology 50: 991–995.
Selkoe D, Kopan R. 2003. Notch and Presenilin: Regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 26: 565–597.
Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, et al. 1997. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89: 629–639.
Short RA, Bowen RL, O'Brien PC, Graff-Radford NR. 2001. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 76: 906–909.
Smith TW, Lippa CF. 1995. Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders. J Neuropathol Exp Neurol 54: 297–303.
Smith MA, Perry G, Atwood CS, Bowen RL. 2003. Estrogen replacement and risk of Alzheimer disease. JAMA 289: 1100.
Soriano S, Kang DE, Fu M, Pestell R, Chevallier N, et al. 2001. Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J Cell Biol 152: 785–794.
Stopa EG, Gonzalez AM, Chorsky R, Corona RJ, Alvarez J, et al. 1990. Basic fibroblast growth factor in Alzheimer's disease. Biochem Biophys Res Commun 171: 690–696.
Styren SD, Mufson EJ, Styren GC, Civin WH, Rogers J. 1990. Epidermal growth factor receptor expression in demented and aged human brain. Brain Res 512: 347–352.
Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, et al. 1996. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348: 429–432.
Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M, et al. 1993. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect 5: 165–176.
Vincent I, Jicha G, Rosado M, Dickson DW. 1997. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci 17: 3588–3598.
Vincent I, Zheng JH, Dickson DW, Kress Y, Davies P. 1998. Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol Aging 19: 287–296.
Willert K, Nusse R. 1998. Beta-catenin: A key mediator of Wnt signaling. Curr Opin Genet Dev 8: 95–102.
Wong PC, Zheng H, Chen H, Becher MW, Sirinathsinghji DJ, et al. 1997. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 387: 288–292.
Yang Y, Geldmacher DS, Herrup K. 2001. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21: 2661–2668.
Yang Y, Mufson EJ, Herrup K. 2003. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci 23: 2557–2563.
Yuasa S, Nakajima M, Aizawa H, Sahara N, Koizumi K, et al. 2002. Impaired cell cycle control of neuronal precursor cells in the neocortical primordium of presenilin-1-deficient mice. J Neurosci Res 70: 501–513.
Zhu X, Rottkamp CA, Raina AK, Brewer GJ, Ghanbari HA, et al. 2000. Neuronal CDK7 in hippocampus is related to aging and Alzheimer disease. Neurobiol Aging 21: 807–813.
Zhu X, Raina AK, Perry G, Smith MA. 2004a. Alzheimer's disease: The two-hit hypothesis. Lancet Neurol 3: 219–226.
Zhu X, McShea A, Harris PLR, Raina AK, Castellani RJ, et al. 2004b. Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1 associated regulator of cyclin B, in Alzheimer's disease. J Neurosci Res 75: 698–703.
Acknowledgements
Work in the authors' laboratories is supported by the National Institutes of Health and the Alzheimer's Association. CSA, GP, and MAS are consultants for and own equity in Voyager Pharmaceutical Corporation.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this entry
Cite this entry
Zhu, X. et al. (2008). Parallels Between Neurodevelopment and Neurodegeneration: A Case Study of Alzheimer's Disease. In: Lajtha, A., Perez-Polo, J.R., Rossner, S. (eds) Handbook of Neurochemistry and Molecular Neurobiology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-32671-9_7
Download citation
DOI: https://doi.org/10.1007/978-0-387-32671-9_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-32670-2
Online ISBN: 978-0-387-32671-9
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences